CN111499750B

CN111499750B - High-neutralization-activity nano antibody for resisting carcinoembryonic antigen and application thereof

Info

Publication number: CN111499750B
Application number: CN202010525911.1A
Authority: CN
Inventors: 宋海鹏; 于建立; 古一; 李飞; 王欢; 刘原源; 周宇航; 黄琪; 李婧婵
Original assignee: Shenzhen Guochuang Nano Antibody Technology Co ltd
Current assignee: Shenzhen Guochuang Nano Antibody Technology Co ltd
Priority date: 2016-12-04
Filing date: 2016-12-04
Publication date: 2022-02-08
Anticipated expiration: 2036-12-04
Also published as: CN111533805B; CN106749667A; CN106749667B; CN111499750A; CN111533805A

Abstract

The invention discloses a high-neutralization activity nano antibody for resisting carcinoembryonic antigen CEA, which has unique 3 complementarity determining regions CDR1, CDR2 and CDR3, and also discloses application of the nano antibody in preparing a tumor treatment drug. The anti-CEA nanobody provided by the invention has specific recognition and binding capacity to CEA antigen, has obvious ADCC effect on tumor cells MKN-45, and can realize accurate imaging of tumor in a mouse body.

Description

High-neutralization-activity nano antibody for resisting carcinoembryonic antigen and application thereof

Technical Field

The invention discloses a nano antibody, belonging to the field of immunology.

Background

Carcinoembryonic antigen (CEA, also known as CEACAM-5 or CD66e) is a glycoprotein with a molecular weight of about 180 kDa. CEA is a member of the immunoglobulin superfamily and contains 7 domains linked to the cell membrane via a Glycosylphosphatidylinositol (GPI) anchor. The 7 domains include a single N-terminal Ig variable domain and 6 domains homologous to Ig constant domains (a1-B1-a 2-B2-A3-B3). CEA was originally classified as a protein expressed only in fetal tissues and has now been identified in several normal adult tissues. Overexpression of CEA is observed in many types of cancer, including colorectal, pancreatic, lung, gastric, hepatoma, breast and thyroid cancers. Thus, CEA has been identified as a tumor associated antigen. CEA is readily cleaved from the cell surface and shed from the tumor into the bloodstream, either directly or via the lymphatic system. Because of this property, serum CEA levels have been used as clinical markers to diagnose and screen for cancer. Furthermore, CEA has also been used as a tumor marker, and immunological assays to measure elevated CEA in the blood of cancer patients have been used clinically for the prognosis and control of cancer.

More importantly, CEA has become a potentially useful tumor-associated antigen for targeted therapy. There have been reported 2 major approaches to cancer treatment using CEA-targeted immunotherapy. One method uses an anti-CEA antibody to elicit the lytic activity of immune cells, particularly by antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC), to eliminate CEA-expressing tumor cells. Another approach is to specifically target CEA-expressing tumor cells by conjugating the anti-CEA antibody or antibody fragment to an effector molecule such as a drug, toxin, radionucleotide, immunomodulator or cytokine, to exert the therapeutic effect of the effector molecule.

Various monoclonal antibodies have been generated against CEA. Chester et al have isolated single chain anti-CEA antibodies from phage display libraries for use in radioimmunoassay and radioimmunotherapy (U.S. Pat. No.5,876,691), followed by humanization of the antibodies (U.S. Pat. No.7,232,888). Radiolabeled anti-CEA antibodies have been used in clinical trials in patients with colorectal cancer.

In camelids (camels, dromedary and llamas) there is a class of heavy chain-only dimeric antibodies H₂It is mainly of the IgG2 and IgG3 type. Such antibodies are also referred to as single domain antibodies or single domain antibodies (sdabs) because they lack a light chain, and thus are referred to as heavy chain-only antibodies (HCAbs), while their antigen-binding site consists of one domain, referred to as a VHH region. Since this type of antibody is a variable region sequence after removal of a constant region, the molecular weight is only 15kD, and the diameter is about 10 nm, and thus it is also called nanobody (Nbs). In addition, such single domain antibodies, called VNARs, are also observed in sharks. This heavy chain-only antibody, originally recognized only as a pathological form of human B-cell proliferative disease (heavy chain disease), may be due to mutations and deletions at the genomic level resulting in the inability of the heavy chain CH1 domain to be expressed, such that the expressed heavy chain lacks CH1 and thus lacks the ability to bind to the light chain, thereby forming a heavy chain dimer.

Nanobodies are comparable in affinity to their corresponding scFv, but surpass scfvs in solubility, stability, resistance to aggregation, refolding, expression yield, and ease of DNA manipulation, library construction, and 3-D structure determination, relative to scfvs of conventional four-chain antibodies.

The nanobody has the smallest functional antigen-binding fragment derived from HCabs in adult camelids, has high stability and high affinity for antigen binding, and can interact with protein cleft and active sites of enzyme, making its action similar to that of inhibitors. Therefore, the nano-antibody can provide a new idea for designing small molecule enzyme inhibitors from peptide-mimetic drugs. Due to the heavy chain only, nanobodies are easier to manufacture than mabs. The unique properties of nanobodies, such as stability in extreme temperature and pH environments, allow for large yields to be produced at low cost. Therefore, the nano antibody has great value in the treatment and diagnosis of diseases and has great development prospect in the antibody target diagnosis and treatment of tumors.

In view of the fact that CEA is more over-expressed in some solid tumors such as colorectal cancer, pancreatic cancer, lung cancer, gastric cancer, hepatoma, breast cancer and thyroid cancer, the development of anti-CEA nanobodies is a new need in the field of antibody technology to fully utilize the super-strong antigen recognition capability of nanobodies, and particularly to recognize some epitopes hidden in crevices or cavities. However, the existence of some structural defects such as low affinity, easy aggregation, short serum half-life and the like due to the low molecular weight of the nanobody prevents the further application of the nanobody. The invention aims to provide an anti-CEA nano antibody which can fully exert the excellent performance of the nano antibody and overcome the inherent defects of the nano antibody, and further exert the application of the nano antibody in CEA detection of human samples and the pharmaceutical field.

Disclosure of Invention

Based on the above object, the present invention provides a nanobody against carcinoembryonic antigen, the variable region of which has 3 complementarity determining regions CDR1, CDR2, CDR3, wherein the CDR1 sequence consists of the amino acid sequence set forth in SEQ ID No.7, the CDR2 sequence consists of the amino acid sequence set forth in SEQ ID No.8, and the CDR3 sequence consists of the amino acid sequence set forth in SEQ ID No. 9.

In a preferred technical scheme, the variable region sequence of the nanobody consists of the amino acid sequence shown in SEQ ID NO. 10.

Secondly, the invention also provides an antibody containing the variable region of the nano antibody, wherein the antibody also has a constant region, and the sequence of the constant region of the antibody consists of the amino acid sequence shown in SEQ ID NO. 11.

Thirdly, the invention also provides a polynucleotide molecule for coding the sequence of the antibody, and the sequence of the polynucleotide molecule is shown by SEQ ID NO. 12.

Fourth, the present invention provides an expression vector comprising the above polynucleotide molecule.

In a preferred embodiment, the vector is pMES 4.

Fifth, the present invention provides a host cell containing the above expression vector.

In a preferred embodiment, the cell is E.coli BL21(DE 3).

Sixth, the invention also provides the application of the nano antibody in preparing tumor treatment medicines.

Finally, the invention provides a composition of a nanobody comprising an amino acid sequence of which the variable region is represented by SEQ ID No.10, and a nanobody comprising an amino acid sequence of which the variable region is represented by SEQ ID No. 16.

The nanometer anti-CEA antibody provided by the invention has unique CDR1, 2 and 3 region sequences, so that the antibody has specific recognition and binding capacity to CEA antigen and does not react with other non-specific cross-reactive proteins. The nano antibody provided by the invention has a remarkable ADCC effect, can induce the cracking of tumor cells MKN-45 expressing CEA, does not have the effect on the MKN-74 cells not expressing CEA, and shows an application prospect in the preparation of tumor treatment drugs. Moreover, the anti-CEA nano antibody provided by the invention can realize accurate imaging of tumors in a mouse body, and shows application prospects in diagnostic reagent preparation and in-vivo imaging technologies.

Drawings

FIG. 1 is a schematic diagram of the structure of the pMES4 expression vector;

FIG. 2 shows the electrophoretic identification of total RNA extracted;

FIG. 3 shows the first round of PCR amplification of antibody variable region gene electrophoresis identification map;

FIG. 4 shows the second round of PCR amplification of antibody variable region gene electrophoresis identification map;

FIG. 5 shows the electrophoretic identification chart of the product of the double digestion reaction with pMES4 vector;

FIG. 6 shows the electrophoretic identification chart of the transformant identified by colony PCR;

FIG. 7 is an SDS-PAGE identification chart of the nanobody;

FIG. 8 is a schematic diagram of the construction of the fusion expression vector;

FIG. 9 shows a double restriction enzyme electrophoresis identification chart of the nanobody and the fusion expression vector;

FIG. 10 is a SDS-PAGE pattern of nanobody purification;

FIG. 11. Nanobody ADCC effect curves;

FIG. 12 is a diagram showing the imaging localization result of the labeled nanobody on the mouse transplanted tumor

Detailed Description

The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. These examples are only illustrative and do not limit the scope of the present invention.

Example 1 construction and screening of anti-CEA Nanobody phage display library

1.1 immunization of alpaca: selecting one healthy adult alpaca, uniformly mixing the recombinant protein CEA and Freund's adjuvant according to the proportion of 1:1, immunizing the alpaca by adopting a back subcutaneous multipoint injection mode according to 6-7 mu g/Kg for four times, wherein the immunization interval is 2 weeks. And collecting alpaca peripheral blood for constructing a phage display library.

1.2 separation of camel source lymphocytes: lymphocytes were analyzed from collected camel-derived anticoagulated whole blood according to routine procedures in the art, every 2.5X 10⁷1mL of RNA isolation reagent was added to each living cell, 1mL of the reagent was extracted with RNA, and the remaining cells were stored at-80 ℃.

1.3 Total RNA extraction: total RNA was extracted according to a routine procedure in the art, and the concentration was adjusted to 1. mu.g/. mu.L with RNase-free water (see FIG. 2 for the results of electrophoretic identification of total RNA extraction).

1.4 reverse transcription Synthesis of cDNA:

reverse transcription of cDNA was carried out using RNA obtained in 1.3 steps as a template according to the instructions of a reverse transcription KIT (Transcriptor first stand cDNA Synthesis KIT from Roche Co.)

1.5 antibody variable region Gene amplification: and carrying out PCR reaction by using cDNA obtained by reverse transcription as a template. Amplification was performed in two rounds, and the primer sequences for the first round of PCR were as follows:

CALL001：GTCCTGGCTGCTCTTCTACAAGG

CALL002：GGTACGTGCTGTTGAACTGTTCC

the PCR reaction conditions and procedures were: : 5min at 95 ℃; 30cycles at 95 ℃ for 30s, 57 ℃ for 30s, 72 ℃ for 30 s; 7min at 72 DEG C

The agarose gel recovery kit gel was used to recover a band of about 700bp, and the nucleic acid concentration was finally adjusted to 5 ng/. mu.l with water (first round PCR product identification is shown in FIG. 3, where 1: first round PCR product; M: molecular weight marker).

The primer sequences for the second round of PCR were as follows:

VHH-Back：GATGTGCAGCTGCAGGAGTCTGGRGGAGG

VHH-For：CTAGTGCGGCCGCTGGAGACGGTGACCTGGGT

the PCR reaction conditions and procedures were: : 5min at 95 ℃; 30s at 95 ℃, 30s at 55 ℃, 30s at 72 ℃ and 15 cycles; 7min at 72 DEG C

PCR products were purified using the PCR product recovery kit (second round PCR product identification is shown in FIG. 4, where 1: second round PCR product; M: molecular weight marker).

1.6 vector construction

pMES4 (purchased from Biovector, whose schematic structure is shown in FIG. 1) was double digested with PstI and BstEII, respectively, to obtain 1.5. mu.g of the digested vector and 450ng of the digested second PCR product, 15. mu. L T4 of DNA ligase was added, buffer and water were supplemented to a total volume of 150. mu.L, ligation was performed overnight at 16 ℃ and the ligation product was recovered. Product recovery was performed using a PCR product recovery kit, eluting with 20. mu.L water. FIG. 5 shows the electrophoretic identification of pMES4 vector double-restriction reaction product (1: pMES4 vector double-restriction product; 2: pMES4 vector; M: molecular weight marker).

1.7 electrotransformation and determination of the storage volume

mu.L of the purified ligation product was taken, and added to a pre-cooled electric cuvette containing 50. mu.L of E.coli TG1 competent cells, and the electric cuvette was placed in an electric converter (ECM630 electric converter, BTX, USA) for electric conversion, and taken out, and the transformant was recovered and cultured. 24 clones were randomly selected and subjected to colony PCR identification (electrophoretic identification is shown in FIG. 6, wherein, 1-23: 23 transformants; N: negative control; M: molecular weight marker). The pool capacity (pool capacity ═ number of clones × dilution × [ positive rate ] PCR assay × 10) was estimated from the PCR positive rate.

The primer sequences are as follows:

MP57：TTATGCTTCCGGCTCGTATG

GIII：CCACAGACAGCCCTCATAG

1.8 phage amplification

Inoculating recovered bacteria solution into YT-AG culture medium, culturing at 37 deg.C and 200rpm until culture OD₆₀₀0.5. 10ml of the bacterial suspension was taken out and added to 4X 10¹⁰VCSM13, 30min at 37 ℃ for static infection. Centrifuging at 4000rpm at normal temperature for 10min, and removing supernatant. The cells were resuspended in 2 XYT-AK (ampicillin and kanamycin-containing) medium and cultured overnight at 37 ℃ and 200 rpm. Centrifuging, taking a supernatant in a 40ml tube, adding 10ml of PEG/NaCl (20%/2.5M) solution, mixing thoroughly, centrifuging, discarding the supernatant, washing the precipitate with 1ml of ice PBS, centrifuging, taking 250 μ l of precooled PEG/NaCl from the supernatant, mixing thoroughly, washing and resuspending.

Determining the phage titer: TG1 was cultured to OD₆₀₀When the phage was diluted with LB medium in a gradient manner at 0.4, the phage TG1 culture was mixed and cultured in a double dilution manner, and the plaque formation in the plate was observed the next day, and the number of plaques was counted on a dilution gradient plate of 30 to 300 and the phage titer (pfu) was calculated according to the following equation.

Phage titer (pfu/ml) dilution times plaque number times 100

1.9 Nanobody screening

Positive clones were screened for recombinant CEA antigen by ELISA. ELISA plates were coated with recombinant CEA antigen, blocked with 5% BSA, and washed with PBST. Mu.l phage supernatant was added to each well and left at 37 ℃ for 1 h. The supernatant was discarded, and a secondary HRP-labeled mouse anti-M13 antibody was added thereto and the mixture was left at 37 ℃ for 1 hour. Discarding the supernatant, adding TMB solution, incubating at room temperature for 5min, adding 2M sulfuric acid stop solution into each well, and reading with microplate reader at 450 nm.

Expression and purification of 1.10 Nano antibody in Escherichia coli

Selecting a clone with a positive phage ELSIA result, extracting plasmids, transforming the plasmid into a strain BL21 competent cell, inducing nano antibody protein expression by IPTG, collecting supernatant (periplasm extract), dialyzing the periplasm extract into PBS, purifying by using Ni-NTA resin, eluting and collecting by using imidazole with different concentrations, and carrying out reduced protein electrophoresis analysis on the collected sample, wherein the result is shown in figure 7 (in figure 7, 1-3: VHH-CEA 1 penetration liquid, low-concentration imidazole elution hybrid protein and elution target protein respectively; 4: molecular weight marker; 5-7: VHH-CEA 2 penetration liquid, low-concentration imidazole elution hybrid protein and elution target protein respectively; and 8-10: VHH-CEA3 penetration liquid, low-concentration imidazole elution hybrid protein and elution target protein respectively).

Through alpaca immunity, cell separation, phage library construction and nano antibody screening, 3 strains of nano antibodies for CEA are screened out. The sequencing results were analyzed using Vector NTI software, and the entries IMGT (see Table II)http:// www.imgt.org/IMGT_vquest) Antibody light and heavy chain genes were analyzed to determine the Framework Regions (FRs) and Complementarity Determining Regions (CDRs) of the variable regions.

The heavy chain nucleotide sequence of the nano antibody VHH-CEA 1 is shown as SEQ ID NO.6, the amino acid sequence of the variable region is shown as SEQ ID NO.4, wherein the amino acid sequence at the 1 st to 20 th positions is FR1, the amino acid sequence at the 21 st to 30 th positions is CDR1, the amino acid sequence at the 31 st to 44 th positions is FR2, the amino acid sequence at the 45 th to 61 th positions is CDR2, the amino acid sequence at the 62 th to 93 th positions is FR3, the amino acid sequence at the 94 th to 104 th positions is CDR3, the amino acid sequence at the 105 th and 115 th positions is FR4, and the amino acid sequence of the constant region is shown as SEQ ID NO. 5.

The heavy chain nucleotide sequence of the nano antibody VHH-CEA 2 is shown as SEQ ID NO.12, the amino acid sequence of the variable region is shown as SEQ ID NO.10, wherein the amino acid sequence at the 1 st to 20 th positions is FR1, the amino acid sequence at the 21 st to 30 th positions is CDR1, the amino acid sequence at the 31 st to 44 th positions is FR2, the amino acid sequence at the 45 th to 57 th positions is CDR2, the amino acid sequence at the 58 th to 89 th positions is FR3, the amino acid sequence at the 90 th to 99 th positions is CDR3, the amino acid sequence at the 100 th position and 110 th positions is FR4, and the amino acid sequence of the constant region is shown as SEQ ID NO. 11.

The heavy chain nucleotide sequence of the nano antibody VHH-CEA3 is SEQ ID NO.18, the amino acid sequence of the variable region is SEQ ID NO.16, wherein the amino acid sequences at the 1 st to 20 th positions are FR1, the amino acid sequences at the 21 st to 30 th positions are CDR1, the amino acid sequences at the 31 st to 44 th positions are FR2, the amino acid sequences at the 45 th to 61 th positions are CDR2, the amino acid sequences at the 62 th to 93 th positions are FR3, the amino acid sequences at the 94 th to 104 th positions are CDR3, the amino acid sequence at the 105 th and 115 th positions is FR4, and the amino acid sequence of the constant region is shown as SEQ ID NO. 17.

Example 2 preparation of anti-CEA Nanobodies

2.1 amplification of original strain TG1 of nano antibody and transformation of Escherichia coli BL21(DE3) by recombinant plasmid of nano antibody

Performing a reaction on an original strain TG1 glycerol strain containing nano antibody nucleic acid according to the ratio of 1: the culture was inoculated at 1000 ratio to 5mL of fresh LB-A medium and cultured overnight at 37 ℃ and 200 rpm. The following day, Plasmid was extracted using a Plasmid mini kit (OMEGA) as per the instructions. After verification, 1ul of the plasmid is transformed into 100ul of competent cells, the competent cells are gently mixed, placed on ice for 30min, hot shocked in a water bath at 42 ℃ for 90s, and cooled in an ice bath for 3 min. 600ul of LB medium was added to the centrifuge tube and cultured with shaking at 37 ℃ for 60 min. 100ul of the supernatant was applied to an LB-A plate using a triangle spreader and cultured overnight at 37 ℃ in an inverted state.

2.2 Induction expression and extraction of Nanobodies

The above monoclonal colonies were picked up in LB-A medium and cultured overnight with shaking at 37 ℃. The next day, the bacterial liquid was taken according to the ratio of 1: adding 100ml of fresh LB-A culture medium in a proportion of 100, and performing shaking culture at 37 ℃ for 3h until the bacterial liquid OD₆₀₀After adding IPTG to a final concentration of 1mM, the mixture was induced overnight at 30 ℃. On the third day, 8000rpm, centrifugation for 10min collected the thalli, and 1.5mL of precooled TES buffer was added to resuspend the pellet. After 2min in ice bath, gently shake for 30s and repeat the cycle 6 times. 3.0ml TES/4 (TES diluted 4 times with water) was added, gently shaken for 30s, and then allowed to stand on an ice bath for 2min, and the shaking and standing steps were repeated a total of 6 times. After centrifugation at 9000rpm at 4 ℃ for 10min, about 4.5mL of the supernatant (periplasmic extract) was collected and subjected to protein electrophoresis.

2.3 purification and characterization of Nanobodies

After resuspending IMAC Sepharose (GE Co., Ltd.), 2ml was taken and added to a gravity column, and the mixture was allowed to stand for 30min to allow Sepharose to naturally settle at the bottom of the gravity column, and the preservation buffer was discharged. Adding 2 times of column volume of nickel sulfate solution (0.1M), and flowing out the nickel sulfate solution at the flow rate of about 8 s/drop; adding 10 times of column volume of balance buffer solution to balance and wash sepharose, and keeping the flow rate unchanged; diluting the sample by 2 times of a balance buffer solution, adding the diluted sample into a gravity column, adjusting the flow rate to be 6 s/drop, and collecting the penetration liquid; adding 10 times of column volume of washing buffer solution to wash sepharose, maintaining the flow rate unchanged, and collecting washing solution; adding elution buffer solution with the volume 3 times of that of the column, maintaining the flow rate at 6 s/drop, and collecting the eluent containing the target protein; finally sepharose was washed by sequentially adding 10 column volumes of equilibration buffer, 10 column volumes of pure water and 10 column volumes of 20% ethanol, and finally 4ml of 20% ethanol was retained to preserve the column. The samples collected above were subjected to SDS-PAGE detection (see FIG. 10, wherein M is molecular weight; 1 is purified nanobody) and Western blot detection, respectively. The results show that the nanobody provided by the invention has high specific binding activity to CEA antigen and does not react with NCA antigen (non-specific cross-reactive protein).

Example 3 affinity Activity of anti-CEA Nanobodies with CEA antigens

3.1 chip antigen coupling

Preparing 20ug/mL working solution of antigen by using sodium acetate buffer solutions (pH 5.5, pH 5.0, pH 4.5 and pH 4.0) with different pH values, preparing 50mM NaOH regeneration solution, analyzing the electrostatic binding between the antigen and the surface of a chip (GE company) under different pH conditions by using a template method in a Biacore T100 protein interaction analysis system instrument, selecting a proper most neutral pH system and adjusting the antigen concentration as the condition during coupling according to the requirement by taking the quantity of signal increase reaching 5 times RL as the standard. Coupling the chip according to a template method carried by the instrument: wherein, the 1 channel selects a blank coupling mode, the 2 channel selects a Target coupling mode, and the Target is set as a designed theoretical coupling quantity. The coupling procedure took approximately 60 min.

3.2 analyte concentration setting Condition exploration and regeneration Condition optimization

A manual sample injection mode is adopted, a1, 2-channel 2-1 mode is selected for sample injection, and the flow rate is set to be 30 uL/min. The sample injection conditions are 120s and 30 uL/min. The regeneration conditions were all 30s, 30 uL/min. The buffer was run continuously empty first until all baselines were stable. The nano antibody solution with larger concentration span is prepared to be configured by running buffer solution, and 200ug/mL, 150ug/mL, 100ug/mL, 50ug/mL, 20ug/mL, 10ug/mL and 2ug/mL are suggested to be arranged. Preparing a regeneration solution, selecting the regeneration solution with four pH gradients of a glutamate acid system: 1.5,2.0,2.5,3.0. A 200ug/mL sample of analyte was manually injected and the 2 channel was observed, regenerating from the most neutral pH regenerating buffer until the line of response after 2 channel regeneration returned to the same height as the baseline. And manually feeding a sample of 200ug/mL of analyte once again, observing the signal change of the 2-1 channel and recording the binding capacity, regenerating by using a regeneration solution which finally returns the response line to the base line in the previous step, then manually feeding a sample of 200ug/mL of analyte again, observing the signal change of the 2-1 channel and recording the binding capacity, comparing with the value of the binding capacity, if the deviation is less than 5%, determining that the regeneration solution with the pH value is the optimal regeneration solution, and if the binding capacity of re-feeding is lower, continuing to perform the experiment by using the regeneration buffer solution with the lower pH value. And taking the selected optimal regeneration solution as a chip surface regeneration reagent after each sample introduction. And respectively injecting analyte concentration samples arranged on the sample injection device, and analyzing the binding capacity of each concentration to finally determine the concentration gradient required by the affinity test.

3.3 affinity assay

And regenerating the solution according to the optimized sample concentration gradient, and testing the affinity between the nano antibody and the antigen by using a template method carried by the instrument (wherein the sample injection condition is set to be 60s and 30 uL/min; the dissociation time is 600s, and the regeneration condition is set to be 30s and 30 uL/min). The signal condition of the 2-1 channel is observed at any time. The affinity testing process takes approximately 200 min.

3.4 analysis of results

The binding dissociation curves for several concentration gradients were selected using a 1: and fitting all curves by using a 1binding mode to finally obtain important parameters such as affinity values, binding constants, dissociation constants and the like.

Table 1: nanobody affinity data

Sample numbering	Affinity of
		VHH-CEA 1	2.40E-09
VHH-CEA 2	3.20E-09
		VHH-CEA 3	1.99E-09

As can be seen from Table 1, the affinity activity of the three strains of anti-CEA nanobodies obtained by the invention and CEA antigen is between 3.20E-09 and 1.99E-09, and the three strains have extremely high affinity, and can be completely applied to the preparation of diagnostic reagents and drugs.

Example 4 overlapping experiments for binding of three different Nanobodies to CEA antigen

4.1 determination of the saturation concentration of antigen

CEA antigen was coated at a concentration of 2ug/ml, 100 ul/well, coated at 4 ℃ for 24h, and washed 5 times. Blocking was performed overnight with 1% BSA as blocking agent and the plate was washed 5 times. Adding different gradient diluted nanometer antibodies into the ELISA plate, performing negative control (negative serum 1:100) and PBS blank control, incubating for 30min at 37 ℃, and washing the plate for 5 times. Adding 1: the goat anti-alpaca IgG labeled with HRP diluted at the ratio of 4000 was incubated at 37 ℃ for 30min, and the plate was washed 5 times. Adding TMB developing solution, incubating at 37 ℃ for 10min, and stopping reaction by 2M sulfuric acid. Reading the light absorption value of 450nm, drawing an antibody saturation curve, and selecting the concentration which does not increase with the increase of the concentration as the saturation concentration according to the result.

4.2 site overlay experiments

The first antibody is added for reaction, the second antibody is added after the plate is washed, the enzyme-labeled secondary antibody is added after the plate is washed, and the color reading of TMB is carried out (the method is the same as 4.1). And calculating the overlapping rate AI of the two antibodies, wherein the AI is more than 50 percent, which indicates that the antigenic sites of the 2 antibodies to be detected are different, the AI is less than 50 percent, which indicates that the antigenic epitopes of the two antibodies to be detected are the same, and the larger the AI value is, the lower the possibility of site overlapping is. The formula is as follows: AI [2 a (1+2) - (a1+ a2) ]/a (1+2) × 100%

A1-first Strain antibody reading

A2-second Strain antibody reading

A (1+2) - - -overlay of 2 antibody readings

Table 2: antibody epitope superposition experiment

The experimental results of this example show that the three strains of nanobodies are directed against different epitopes of the CEA antigen, which indicates that the three strains of nanobodies can be used as a composition complementary to the epitopes for combined application in diagnosis and treatment of nanobodies, thereby increasing the efficiency of diagnosis or treatment.

Example 5 determination of ADCC Activity induced by anti-CEA Nanobodies

And (3) performing PCR amplification on the nano antibody gene by using a primer and taking VHH-pMES4 as a template. The primer sequences are as follows:

F:CCGAAATTCGAGTCTGGAGGAGG

R:GGAAGATCTCTGGGTCCCCTGGCCC

the PCR product was double-digested with the fusion expression vector pFUSE-hIgG1-Fc using EcoRI and Bgl II restriction enzymes (NEB), respectively (see FIG. 8). The vector after double digestion was ligated with the nanobody gene overnight using T4 ligase (NEB) (see FIG. 9, wherein 1-3: VHH-pFUSE-hIgG 1-Fc; 4: negative control; M: molecular weight marker), and after transformation of DH 5. alpha. competence, plasmids were extracted using endotoxin-free macroextraction kit (Tiangen). Transfecting human 293 cells, and purifying the single domain antibody of CEA from the culture supernatant of the 293 cells by using a protein A affinity chromatography method.

MKN-45 and MKN-74 cells (3X 10) were cultured in 96-well cell microwell plates⁴Per well) for 48 hours, and then LAK cells (lymphokine activated killer cells), anti-CEA nanobodies VHH-

CEA

1, 2, and 3, or IgG antibody controls were added according to a specific ratio, LAK cells to target cells at a ratio of 1, 5, 10, 15, 20:1, antibody concentrations of 2 μ g/ml each. After incubation at 37 ℃ for 6 hours in a 5% CO2 environment, LAK cells and dead tumor cells were aspirated and cell viability was determined using the MTS method.

Cytotoxicity (%) ═ OD of experimental target cells₄₉₀OD of control target cells₄₉₀]The x 100 results show that the anti-CEA nanobodies VHH-

CEA

1, 2 and 3 are all able to significantly induce ADCC activity of LAK cells with tumor cell lysis rates between 45-75%, and this lysis is not observed in MKN-74 cells that do not express CEA (see fig. 11).

Example 6 in vivo imaging localization of anti-CEA Nanobodies to xenograft tumor mice

MKN-45 cell solution (5X 10) is prepared⁶MKN-45 cells in 0.2ml PBS), subcutaneously injected into the back of SCID mice, and administered with metallotechnetium by tail vein injection after tumor growth for 20 days⁹⁹The labelled nanobodies VHH-

CEA

1, 2 and 3, or control antibody IgG (30. mu.g/0.1 ml), were used to image-localize the transplanted tumors in a mouse in vivo imaging system.

The results show that the anti-CEA nano antibody provided by the invention can realize accurate imaging of tumors in mice and can be used for accurate in vivo diagnosis of related tumors in the future (see FIG. 12).

Sequence listing

<110> Shenzhen Shang Nanobody technology Limited

<120> high-neutralization-activity nano antibody for resisting carcinoembryonic antigen and application thereof

<160> 18

<170> SIPOSequenceListing 1.0

<210> 1

<211> 10

<212> PRT

<213> Lama pacos

<400> 1

Gly Phe Thr Phe Ser Arg Tyr Ala Met Arg

1 5 10

<210> 2

<211> 17

<212> PRT

<213> Lama pacos

<400> 2

Ala Ile Ser Ser Ala Gly Gly Thr Arg Asp Tyr Ala Asp Ser Val Lys

1 5 10 15

Gly

<210> 3

<211> 11

<212> PRT

<213> Lama pacos

<400> 3

Val Pro Asp Thr Asn Thr Val Asn Asn Ala Tyr

1 5 10

<210> 4

<211> 109

<212> PRT

<213> Lama pacos

<400> 4

Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser

1 5 10 15

Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr Ala Met Arg Trp Asp

20 25 30

Arg Arg Ala Pro Gly Lys Glu Arg Glu Leu Val Ala Ala Ile Ser Ser

35 40 45

Ala Gly Gly Thr Arg Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr

50 55 60

Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Ser

65 70 75 80

Leu Asn Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Asp

85 90 95

Thr Asn Thr Val Asn Asn Ala Tyr Trp Gly Gln Gly Thr

100 105

<210> 5

<211> 231

<212> PRT

<213> Lama pacos

<400> 5

Ala His His Ser Glu Asp Pro Ser Ser Lys Cys Pro Lys Cys Pro Gly

1 5 10 15

Pro Glu Leu Leu Gly Gly Pro Thr Val Phe Ile Phe Pro Pro Lys Pro

20 25 30

Lys Asp Val Leu Ser Ile Thr Arg Lys Pro Glu Val Thr Cys Val Val

35 40 45

Val Asp Val Gly Lys Glu Asp Pro Glu Ile Glu Phe Ser Trp Ser Val

50 55 60

Asp Asp Thr Glu Val His Thr Ala Glu Thr Lys Pro Lys Glu Glu Gln

65 70 75 80

Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Pro Ile Gln His Gln

85 90 95

Asp Trp Leu Thr Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Ala

100 105 110

Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Ala Lys Gly Gln Thr

115 120 125

Arg Glu Pro Gln Val Tyr Ala Leu Ala Pro His Arg Glu Glu Leu Ala

130 135 140

Lys Asp Thr Val Ser Val Thr Cys Leu Val Lys Gly Phe Phe Pro Ala

145 150 155 160

Asp Ile Asn Val Glu Trp Gln Arg Asn Gly Gln Pro Glu Ser Glu Gly

165 170 175

Thr Tyr Ala Thr Thr Leu Pro Gln Leu Asp Asn Asp Gly Thr Tyr Phe

180 185 190

Leu Tyr Ser Lys Leu Ser Val Gly Lys Asn Thr Trp Gln Gln Gly Glu

195 200 205

Val Phe Thr Cys Val Val Met His Glu Ala Leu His Asn His Ser Thr

210 215 220

Gln Lys Ser Ile Ser Gln Ser

225 230

<210> 6

<211> 1038

<212> DNA

<213> Lama pacos

<400> 6

gagtctgggg gaggcttggt gcagcctggg gggtctctga gactctcctg tgcagcctct 60

ggattcacgt tcagtaggta tgccatgagg tgggaccgcc gggctccagg aaaggagcgc 120

gagttggtcg cagctatttc tagtgctggc ggtactaggg actacgcaga ctccgtgaag 180

ggccgattca ccatctccag agacaatgcc aagaacacgg tgtatctgca aatgaacagc 240

ctgaacccgg aggacacggc cgtgtattac tgtgccgcag tcccggatac aaatactgtg 300

aacaatgcct actggggcca ggggacccag gtcaccgtct cctcggcgca ccacagcgaa 360

gaccccagct ccaagtgtcc caaatgccca ggccctgagc tccttggagg gcccacggtc 420

ttcatcttcc ccccgaaacc caaggacgtc ctctccatca cccgaaaacc tgaggtcacg 480

tgcgttgtgg tggacgtggg taaggaagac cctgagatcg agttcagctg gtccgtggat 540

gacacagagg tacacacggc tgagacaaag ccaaaggagg aacagttcaa cagcacgtac 600

cgcgtggtca gcgtcctgcc catccagcac caggactggc tgacggggaa ggaattcaag 660

tgcaaggtca acaacaaagc tctcccagcc cccatcgaga ggaccatctc caaggccaaa 720

gggcagaccc gggagccgca ggtgtacgcc ctggccccac accgggaaga gctggccaag 780

gacaccgtga gcgtaacctg cctggtcaaa ggcttcttcc cagctgacat caacgttgag 840

tggcagagga acgggcagcc ggagtcagag ggcacctacg ccaccacgct gccccagctg 900

gacaacgacg ggacctactt cctctacagc aaactctccg tgggaaagaa cacgtggcag 960

cagggagaag tcttcacctg tgtggtgatg cacgaggctc tacacaatca ctccacccag 1020

aaatccatct cccagtct 1038

<210> 7

<211> 10

<212> PRT

<213> Lama pacos

<400> 7

Gly Phe Thr Ile Ser Asp Tyr Gln Met Glu

1 5 10

<210> 8

<211> 13

<212> PRT

<213> Lama pacos

<400> 8

Phe Ile Thr Asn Thr Asn Tyr Ala Asp Ser Val Lys Gly

1 5 10

<210> 9

<211> 10

<212> PRT

<213> Lama pacos

<400> 9

Arg His Tyr Val Gln Arg Trp Asn Asp Tyr

1 5 10

<210> 10

<211> 104

<212> PRT

<213> Lama pacos

<400> 10

Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser

1 5 10 15

Cys Ala Ala Ser Gly Phe Thr Ile Ser Asp Tyr Gln Met Glu Trp His

20 25 30

Arg Gln Thr Pro Gly Arg Glu Arg Glu Leu Ile Ala Phe Ile Thr Asn

35 40 45

Thr Asn Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp

50 55 60

Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Ala Asn Leu Asn Thr Glu

65 70 75 80

Asp Thr Ala Val Tyr Phe Cys His Ala Arg His Tyr Val Gln Arg Trp

85 90 95

Asn Asp Tyr Trp Gly Gln Gly Thr

100

<210> 11

<211> 231

<212> PRT

<213> Lama pacos

<400> 11

Ala His His Ser Glu Asp Pro Ser Ser Lys Cys Pro Lys Cys Pro Gly

1 5 10 15

Pro Glu Leu Leu Gly Gly Pro Thr Val Phe Ile Phe Pro Pro Lys Pro

20 25 30

Lys Asp Val Leu Ser Ile Thr Arg Lys Pro Glu Val Thr Cys Val Val

35 40 45

Val Asp Val Gly Lys Glu Asp Pro Glu Ile Glu Phe Ser Trp Ser Val

50 55 60

Asp Asp Thr Glu Val His Thr Ala Glu Thr Lys Pro Lys Glu Glu Gln

65 70 75 80

Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Pro Ile Gln His Gln

85 90 95

Asp Trp Leu Thr Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Ala

100 105 110

Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Ala Lys Gly Gln Thr

115 120 125

Arg Glu Pro Gln Val Tyr Ala Leu Ala Pro His Arg Glu Glu Leu Ala

130 135 140

Lys Asp Thr Val Ser Val Thr Cys Leu Val Lys Gly Phe Phe Pro Ala

145 150 155 160

Asp Ile Asn Val Glu Trp Gln Arg Asn Gly Gln Pro Glu Ser Glu Gly

165 170 175

Thr Tyr Ala Thr Thr Leu Pro Gln Leu Asp Asn Asp Gly Thr Tyr Phe

180 185 190

Leu Tyr Ser Lys Leu Ser Val Gly Lys Asn Thr Trp Gln Gln Gly Glu

195 200 205

Val Phe Thr Cys Val Val Met His Glu Ala Leu His Asn His Ser Thr

210 215 220

Gln Lys Ser Ile Ser Gln Ser

225 230

<210> 12

<211> 1023

<212> DNA

<213> Lama pacos

<400> 12

gagtctgggg gaggcttggt gcagcctggg gggtctctga gactctcctg tgcagcctct 60

ggcttcacca tcagtgacta tcagatggaa tggcatcgcc agactccagg gagggagcgc 120

gaattgatcg catttataac taacacaaac tatgcggatt ccgtgaaggg ccgattcacc 180

atctccagag acaatgccaa gaacacggtg tatctgcaaa tggccaacct gaatactgag 240

gacacggccg tatatttctg tcacgcaagg cattatgtcc aacgctggaa tgactactgg 300

ggccagggga cccaggtcac cgtctcctcg gcgcaccaca gcgaagaccc cagctccaag 360

tgtcccaaat gcccaggccc tgagctcctt ggagggccca cggtcttcat cttccccccg 420

aaacccaagg acgtcctctc catcacccga aaacctgagg tcacgtgcgt tgtggtggac 480

gtgggtaagg aagaccctga gatcgagttc agctggtccg tggatgacac agaggtacac 540

acggctgaga caaagccaaa ggaggaacag ttcaacagca cgtaccgcgt ggtcagcgtc 600

ctgcccatcc agcaccagga ctggctgacg gggaaggaat tcaagtgcaa ggtcaacaac 660

aaagctctcc cagcccccat cgagaggacc atctccaagg ccaaagggca gacccgggag 720

ccgcaggtgt acgccctggc cccacaccgg gaagagctgg ccaaggacac cgtgagcgta 780

acctgcctgg tcaaaggctt cttcccagct gacatcaacg ttgagtggca gaggaacggg 840

cagccggagt cagagggcac ctacgccacc acgctgcccc agctggacaa cgacgggacc 900

tacttcctct acagcaaact ctccgtggga aagaacacgt ggcagcaggg agaagtcttc 960

acctgtgtgg tgatgcacga ggctctacac aatcactcca cccagaaatc catctcccag 1020

tct 1023

<210> 13

<211> 10

<212> PRT

<213> Lama pacos

<400> 13

Gly Phe Thr Phe Ser Arg Tyr Ala Met Arg

1 5 10

<210> 14

<211> 17

<212> PRT

<213> Lama pacos

<400> 14

Ala Ile Ser Ser Ala Gly Gly Ser Arg Asp Tyr Ala Asp Ser Val Lys

1 5 10 15

Gly

<210> 15

<211> 11

<212> PRT

<213> Lama pacos

<400> 15

Val Pro Asp Thr Asn Thr Val Asn Asn Ala Tyr

1 5 10

<210> 16

<211> 115

<212> PRT

<213> Lama pacos

<400> 16

Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser

1 5 10 15

Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr Ala Met Arg Trp Asp

20 25 30

Arg Arg Ala Pro Gly Lys Glu Arg Glu Leu Val Ala Ala Ile Ser Ser

35 40 45

Ala Gly Gly Ser Arg Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr

50 55 60

Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr Leu Gln Met Asn Asn

65 70 75 80

Leu Asn Pro Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ala Val Pro Asp

85 90 95

Thr Asn Thr Val Asn Asn Ala Tyr Trp Gly Gln Gly Thr Gln Val Thr

100 105 110

Val Ser Ser

115

<210> 17

<211> 231

<212> PRT

<213> Lama pacos

<400> 17

Ala His His Ser Glu Asp Pro Ser Ser Lys Cys Pro Lys Cys Pro Gly

1 5 10 15

Pro Glu Leu Leu Gly Gly Pro Thr Val Phe Ile Phe Pro Pro Lys Pro

20 25 30

Lys Asp Val Leu Ser Ile Thr Arg Lys Pro Glu Val Thr Cys Val Val

35 40 45

Val Asp Val Gly Lys Glu Asp Pro Glu Ile Glu Phe Ser Trp Ser Val

50 55 60

Asp Asp Thr Glu Val His Thr Ala Glu Thr Lys Pro Lys Glu Glu Gln

65 70 75 80

Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Pro Ile Gln His Gln

85 90 95

Asp Trp Leu Thr Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Ala

100 105 110

Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Ala Lys Gly Gln Thr

115 120 125

Arg Glu Pro Gln Val Tyr Ala Leu Ala Pro His Arg Glu Glu Leu Ala

130 135 140

Lys Asp Thr Val Ser Val Thr Cys Leu Val Lys Gly Phe Phe Pro Ala

145 150 155 160

Asp Ile Asn Val Glu Trp Gln Arg Asn Gly Gln Pro Glu Ser Glu Gly

165 170 175

Thr Tyr Ala Thr Thr Leu Pro Gln Leu Asp Asn Asp Gly Thr Tyr Phe

180 185 190

Leu Tyr Ser Lys Leu Ser Val Gly Lys Asn Thr Trp Gln Gln Gly Glu

195 200 205

Val Phe Thr Cys Val Val Met His Glu Ala Leu His Asn His Ser Thr

210 215 220

Gln Lys Ser Ile Ser Gln Ser

225 230

<210> 18

<211> 1053

<212> DNA

<213> Lama pacos

<400> 18

gagtctgggg gaggcttggt gcagcctggg gggtctctga gactctcctg tgcagcctct 60

ggattcacgt tcagtaggta tgccatgagg tgggaccgcc gggctccagg aaaggagcgc 120

gagttggtcg cagctatttc tagtgctggc ggtagtaggg actacgcaga ctccgtgaag 180

ggccgattca ccatctccag agacaatgcc aagaacacgg tgtatctgca aatgaacaac 240

ctgaacccgg aggacacggc cgtgtattac tgtgccgcag tcccggatac taatactgtg 300

aacaatgcct actggggcca ggggacccag gtcaccgtct cctcagtcac cgtctcctcg 360

gcgcaccaca gcgaagaccc cagctccaag tgtcccaaat gcccaggccc tgagctcctt 420

ggagggccca cggtcttcat cttccccccg aaacccaagg acgtcctctc catcacccga 480

aaacctgagg tcacgtgcgt tgtggtggac gtgggtaagg aagaccctga gatcgagttc 540

agctggtccg tggatgacac agaggtacac acggctgaga caaagccaaa ggaggaacag 600

ttcaacagca cgtaccgcgt ggtcagcgtc ctgcccatcc agcaccagga ctggctgacg 660

gggaaggaat tcaagtgcaa ggtcaacaac aaagctctcc cagcccccat cgagaggacc 720

atctccaagg ccaaagggca gacccgggag ccgcaggtgt acgccctggc cccacaccgg 780

gaagagctgg ccaaggacac cgtgagcgta acctgcctgg tcaaaggctt cttcccagct 840

gacatcaacg ttgagtggca gaggaacggg cagccggagt cagagggcac ctacgccacc 900

acgctgcccc agctggacaa cgacgggacc tacttcctct acagcaaact ctccgtggga 960

aagaacacgt ggcagcaggg agaagtcttc acctgtgtgg tgatgcacga ggctctacac 1020

aatcactcca cccagaaatc catctcccag tct 1053

Claims

1. A nanobody against carcinoembryonic antigen, the variable region of which has 3 complementarity determining regions CDR1, CDR2, CDR3, wherein the CDR1 sequence consists of the amino acid sequence set forth in SEQ ID No.7, and the CDR2 sequence consists of the amino acid sequence set forth in SEQ ID No.8, and the CDR3 sequence consists of the amino acid sequence set forth in SEQ ID No. 9.

2. The nanobody of claim 1, wherein the variable region sequence of the nanobody consists of the amino acid sequence set forth in SEQ ID No. 10.

3. An antibody comprising the variable region of the nanobody of claim 2, wherein the antibody further comprises a constant region consisting of the amino acid sequence set forth in SEQ ID No. 11.

4. A polynucleotide molecule encoding the sequence of the antibody of claim 3, said polynucleotide molecule having the sequence shown in SEQ ID No. 12.

5. An expression vector comprising the polynucleotide molecule of claim 4.

6. The vector of claim 5, wherein said vector is pMES 4.

7. A host cell comprising the expression vector of claim 6.

8. The host cell of claim 7, wherein the cell is E.coli BL21(DE 3).

9. Use of the antibody of claim 3 for the preparation of a medicament for the treatment of tumors.

10. A composition comprising a nanobody having an amino acid sequence represented by SEQ ID No.10 as a variable region, which further comprises a nanobody having an amino acid sequence represented by SEQ ID No.16 as a variable region.